AVA6000 FAP-Released Doxorubicin Posts 90% Disease Control in Salivary Gland Cancer

AVA6000 is a fibroblast activation protein-cleavable peptide-drug conjugate designed to release doxorubicin preferentially in the tumor microenvironment. In the first-in-human Phase Ia/Ib trial (NCT04969835), the salivary gland cancer cohort across Phase Ia/Ib (n=30) had 2 partial responses and 25 stable diseases, for a 90% disease control rate, with median PFS not reached at >5 months’ median follow-up. Phase Ib safety included fatigue 56%, alopecia 52%, nausea 44%, anemia 26%, neutropenia 22%, grade 3–4 neutropenia 11%, and no grade 3–4 cardiac events or clinically meaningful LVEF decline despite high cumulative doxorubicin-equivalent exposure.